About this trial
Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate (ADC). It received accelerated FDA approval in November 2022 for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, orprimary peritoneal cancer who have received 1 to 3 prior systemic treatment regimens. FRα, also known as folate receptor 1 (FOLR1), has limited expression on normal tissues but is elevated in most ovarian cancers,which makes it an attractive target for the development of novel therapies.
The GLORIOSA trial will evaluate maintenance therapy with MIRV + bevacizumab vs. bevacizumab alone in patients with FRα-high recurrent platinum sensitive ovarian cancer (rPSOC), who demonstrated CR, partial response (PR), or stable disease (SD) following 2nd Line triplet therapy.
Patient Profile
Patients with FRα-high recurrent platinum sensitive ovarian cancer who have received prior platinum based chemotherapy plus bevacizumab.
Where’s this trial being run?
Beaumont Hospital, Bon Secours Cork, Cork University Hospital, Sligo University Hospital, St James’s Hospital, University Hospital Galway, and University Hospital Waterford
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | GLORIOSA |
|---|---|
| Number: | 22-18 |
| Full Title: | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) |
| Principal Investigator: | Prof. Patrick Morris |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Immunogen |
| Recruitment Started: |
Global: Feb 2024 Ireland: Nov 2024 |
| Global Recruitment Target: | 418 |
|---|---|
| Ireland Recruitment Target: | 20 |